Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo

International Journal of Oncology

Volumn 39, Issue 1, 2011, Pages 23-31

  Yamaguchi, Takayuki ^a   Kakefuda, Reina ^a   Tajima, Nobuyuki ^a   Sowa, Yoshihiro ^b   Sakai, Toshiyuki ^b  

^a JAPAN TOBACCO INC   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Antitumor activity; GSK1120212; JTP 74057; MEK; PI3K Akt

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; FLUOROURACIL; JTP 74057; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; N [3 [3 CYCLOPROPYL 5 (2 FLUORO 4 IODOPHENYLAMINO) 6,8 DIMETHYL 2,4,7 TRIOXO 3,4,6,7 TETRAHYDRO 2H PYRIDO[4,3 D]PYRIMIDIN 1 YL]PHENYL]ACETAMIDE; OXALIPLATIN; PROTEIN KINASE B INHIBITOR; UNCLASSIFIED DRUG;

ACHROMOBACTER DENITRIFICANS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT DURATION; TUMOR REGRESSION; UPREGULATION; XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG SYNERGISM; FEMALE; FLUOROURACIL; HCT116 CELLS; HT29 CELLS; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79956018943     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1015     Document Type: Article

References (34)

1. Sebolt-Leopold JS and Herrera R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937-947, 2004 (Pubitemid 39626217)
2. McCubrey JA, Milella M, Tafuri A, et al: Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr Opin Investig Drugs 9: 614-630, 2008.
3. Bos JL: Ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689, 1989
4. Adjei AA: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93: 1062-1074, 2001.
5. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
6. Thomas NE: BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res 16: 97-103, 2006.
7. Yuen ST, Davies H, Chan TL, et al: Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 62: 6451-6455, 2002. (Pubitemid 35364105)
8. Cohen Y, Xing M, Mambo E, et al: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95: 625-627, 2003. (Pubitemid 36553510)
9. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454-1457, 2003. (Pubitemid 36373628)
10. Blume-Jensen P and Hunter T: Oncogenic kinase signaling. Nature 411: 355-365, 2001.
11. Porter AC and Vaillancourt RR: Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 17: 1343-1352, 1998. (Pubitemid 28458404)
12. Sebolt-Leopold JS, Dudley DT, Herrera R, et al: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5: 810-816, 1999 (Pubitemid 29318616)
13. Rinehart J, Adjei AA, Lorusso PM, et al: Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22: 4456-4462, 2004 (Pubitemid 41185111)
14. Yeh TC, Marsh V, Bernat BA, et al: Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 13: 1576-1583, 2007 (Pubitemid 46450450)
15. Solit DB, Garraway LA, Pratilas CA, et al: BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358-362, 2006. (Pubitemid 43128863)
16. Sowa Y, Orita T, Minamikawa-Hiranabe S, Mizuno T, Nomura H and Sakai T: Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biohem Biophys Res Commun 241: 142-150, 1997
17. 1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-required kinase pathway. Mol Cancer Ther 6: 1579-1587, 2007 (Pubitemid 46954025)
18. Nishimura N, Furukawa Y, Sutheesophon K, et al: Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c. Oncogene 22: 4074-4082, 2003. (Pubitemid 36819647)
19. Kip1 via multiple signaling pathways. Cell Cycle 4: 87-95, 2005
20. Shindoh N, Mori M, Terada Y, et al: YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model. Int J Oncol 32: 545-555, 2008. (Pubitemid 351330460)
21. INK4b-inductive compound, as a novel MEK1/2 inhibitor. Cancer Sci 98: 1809-1816, 2007
22. Davies BR, Logie A, McKay JS, et al: AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/ pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6: 2209-2219, 2007 (Pubitemid 47294749)
23. Mirzoeva OK, Das D, Heiser LM, et al: Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 69: 565-572, 2009
24. Hoeflich KP, O'Brien C, Boyd Z, et al: In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 15: 4649-4664, 2009
25. Yang JY, Chang CJ, Xia W, et al: Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. Cancer Res 70: 4709-4718, 2010.
26. Zeghari-Squalli N, Raymond E, Cvitkovic E and Goldwasser F: Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 5: 1189-1196, 1999 (Pubitemid 29233237)
27. Akutsu M, Suzuki K, Tsunoda S, Kano Y and Miura Y: Efficacy of combination therapy of irinotecan (CPT-11) and other anticancer drugs: evaluation in B-lymphoid tumor cell lines. Jpn J Cancer Chemotherapy 21: 1607-1611, 1994
28. Balmanno K, Chell SD, Gillings AS, Hayat S and Cook SJ: Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer 125: 2332-2341, 2009
29. Kip1. Cancer Res 65: 4870-4880, 2005 (Pubitemid 40740826)
30. Tetsu O and McCormick F: Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 3: 233-245, 2003. (Pubitemid 37443879)
31. Samuels Y, Wang Z and Bardelli A: High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554, 2004
32. Nassif NT, Lobo GP, Wu X, et al: PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene 23: 617-628, 2004 (Pubitemid 38175018)
33. Woosterl R, Cornwell W, Jing J, et al: Models for response to the MEK inhibitor GSK1120212 confirm RAS and BRAF mutations as predictive biomarkers and suggest other, unexpected tumor types for clinical evaluation. Eur J Cancer (Suppl) 6: S33-S34, 2008.
34. Allen WL and Johnston PG. Role of genomic markers in colorectal cancer treatment. J Clin Oncol 23: 4545-4552, 2005. (Pubitemid 46196585)